GIANANTONIO SAVIOLA

Dr. GIANANTONIO SAVIOLA


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2017 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
GIANANTONIO SAVIOLAGIANANTONIO SAVIOLA
GIANANTONIO SAVIOLA
LALul Abdi-Ali
Lul Abdi-Ali
MPMaria Rosaria Povino
Maria Rosaria Povino
LCLorella Campostrini
Lorella Campostrini
SSSilvano Sacco
Silvano Sacco
Luca Dalle CarbonareLuca Dalle Carbonare
Luca Dalle Carbonare

1 November 2019 in Cells
Verified
Journal Article
Open access
PDF file
MDMichela Deiana
Michela Deiana
Giovanni MalerbaGiovanni Malerba
Giovanni Malerba
Luca Dalle CarbonareLuca Dalle Carbonare
Luca Dalle Carbonare
SCSAMUELE CHERI
SAMUELE CHERI
CPCristina Patuzzo
Cristina Patuzzo
Maria Teresa ValentiMaria Teresa Valenti
Maria Teresa Valenti
Osteoarthritis (OA) is predominantly characterized by the progressive degradation of articular cartilage, the connective tissue produced by chondrocytes, due to an imbalance between anabolic and catabolic processes. In addition, physical activity (PA) is recognized as an important tool for counteracting OA. To evaluate PA effects on the chondrocyte lineage, we analyzed the expression of SOX9, COL2A1, and COMP in circulating progenitor cells following a half marathon (HM) performance. Therefore, we studied in-depth the involvement of metabolites affecting chondrocyte lineage, and we compared the metabolomic profile associated with PA by analyzing runners’ sera before and after HM performance. Interestingly, this study highlighted that metabolites involved in vitamin B6 salvage, such as pyridoxal 5′-phosphate and pyridoxamine 5′-phosphate, were highly modulated. To evaluate the effects of vitamin B6 in cartilage cells, we treated differentiated mesenchymal stem cells and the SW1353 chondrosarcoma cell line with vitamin B6 in the presence of IL1β, the inflammatory cytokine involved in OA. Our study describes, for the first time, the modulation of the vitamin B6 salvage pathway following PA and suggests a protective role of PA in OA through modulation of this pathway.

1 August 2023 in Current Rheumatology Reviews
Verified
Journal Article
Closed access
PDF file
SRSergio Rosini
Sergio Rosini
GIANANTONIO SAVIOLAGIANANTONIO SAVIOLA
GIANANTONIO SAVIOLA
LCLaura Comini
Laura Comini
LMLuigi Molfetta
Luigi Molfetta
Osteoarthritis (OA) is a chronic disease with both degenerative and inflammatory charac-teristics, affecting the osteochondral unit with the involvement of cartilage, subchondral bone and periarticular tissues. OA can produce chronic pain with neuropathic and inflammatory characteris-tics, leading to an increased disability. OA is secondary to many predisposing factors where the inflammatory process plays a key role. To manage OA, it would seem logical to block the factors influencing the inflammatory process at different levels, T lymphocytes, neutrophils, and the balance between phenotype-1 macrophages (M1, pro-inflammatory) and phenotype-2 macrophages (M2 anti-inflammatory), the managing cells. The efforts to repair and rebuild the lost cartilage and the attempts to implant autologous or heterologous material, with or without growth factors and the administration of drugs or the use of medical devices, have failed their objective. TNF-alpha and IL-1 inhibitors can only have a transient effect on pain; intra-articular oxidized Low-Density Lipoproteins are able to stimulate the activation of M2, while growth factors need to be better investigated. Also, intra-articular injections of mesenchymal stem cells (MSC) can inhibit the proliferation of T-lymphocytes, leading to cartilage repair and to osteophytes inhibition thanks to the release of exosomes, nanosized particles which are the active components. Gut microbiota has a potential role in the development of OA and could be able to influence the response to therapeutic agents.

1 December 2020 in Minerva Medica
Verified
Journal Article
Closed access
GIANANTONIO SAVIOLAGIANANTONIO SAVIOLA
GIANANTONIO SAVIOLA
PFPaolo Ferrari
Paolo Ferrari
ENErnesto Niccolò
Ernesto Niccolò
ACAndrea Casabella
Andrea Casabella
FGFrancesco Ghellere
Francesco Ghellere
LMLuigi Molfetta
Luigi Molfetta
BACKGROUND: Knee replacement surgery is one of the most common surgical procedures performed worldwide. Unfortunately, knee prostheses can become painful over time, necessitating appropriate analgesic treatment. Bisphosphonates such as clodronate (CLO) may play an important role in the treatment of painful knee prostheses by virtue of its analgesic and anti-inflammatory properties. METHODS: In this prospective open label pilot study, eighteen consecutive patients aged 73.2 +/- 8.9 years affected by knee painful prosthesis and osteoarthritis were treated with a rehabilitation cycle in addition to i.v. or i.m. CLO. Induction dose was 2.0-2.1g, followed by a weekly dose of 200 mg (i.m.) for 6 months. Visual analogue scale (VAS) pain score and Tegner Lysholm Score (TLS) were used to assess improvement following CLO treatment. RESULTS: Thirteen out of 18 patients completed the 6-month follow-up. VAS pain score decreased from 8.1 +/- 1.8 at baseline to 5.2.6 (P<0.05) and TLS increased from 40.4 +/- 203 at baseline to 62.7 +/- 24.1 at 6 months (P<0.05). Univariate regression revealed that among a range of variables, BMI was positively correlated with VAS (r=0.73, P=0.004) and lower TLs after 1 month (r=-0.62, P=0.006). CONCLUSIONS: CLO in association with rehabilitation exercises can reduce pain and ameliorate the functionality of painful knee prostheses. Administration of a high dose (induction dose) of CLO every 3 months appears to be the most effective regimen compared to a weekly maintenance dose.

1 November 2024 in Minerva Medica
Verified
Journal Article
Closed access
SRSergio Rosini
Sergio Rosini
SRStefano Rosini
Stefano Rosini
GIANANTONIO SAVIOLAGIANANTONIO SAVIOLA
GIANANTONIO SAVIOLA
LMLuigi Molfetta
Luigi Molfetta
Article: Adenosine triphosphate: a new player in complex regional pain syndrome type 1 - Minerva Medica 2024 Aug 05 - Minerva Medica - Journals

1 December 2018 in Medicine
Verified
Journal Article
Open access
GIANANTONIO SAVIOLAGIANANTONIO SAVIOLA
GIANANTONIO SAVIOLA
LALul Abdi-Ali
Lul Abdi-Ali
SSSilvano Sacco
Silvano Sacco
LCLaura Comini
Laura Comini
KPKatrin Plewnia
Katrin Plewnia
AOAlfredo Orrico
Alfredo Orrico
The mechanisms of action of MTX (methotrexate) in the treatment of RA (rheumatoid arthritis) and PsA (psoriatic arthritis) is related to its antifolic activity, due to the high affinity for enzymes that require folate cofactors as dihydrofolate reductase and to the anti-inflammatory activity derivated from the inhibition of thymidylate synthetase that leads to the over-production of adenosine. Our patient was a 41-year-old female, affected by PsA in treatment since 2 years with low-dose methylprednisolone and low-dose subcutaneous MTX. The treatment was effective. The patient subacutely developed a severe paraparesis with impossibility of gait or standing without aid and was admitted to a Neurology Department where the cause of the paraparesis was not clear in spite of accurate radiological neurophysiologic and laboratory tests. Therefore, she was admitted in a rehabilitation unit. Paraparesis in PsA patient in treatment with methotrexate. MTX toxicity was hypothesized; therefore the drug was discontinued while i.m. folic acid and cyanocobalamin were administered for 20 days. The diagnosis was clinical, based on neurological examination (paraparesis) and on the chronic use of MTX (hypothesis of toxicity). The patient obtained a complete resolution of paraparesis. Genetic analyses showed associated a compound heterozygosity for the c.1298A>C and c.677C>T variants of methylenetetrahydrofolate reductase (MTHFR) gene. Neurological side effects of MTX are uncommon. In literature no previous case of MTX induced paraparesis in patients treated with low-dose MTX for chronic arthritis has been described. The association between the gene polymorphisms of MTHFR (c.1298A>C and c.677C>T) and MTX toxicity in arthritis patients is confirmed. The case also confirms that folates are a precious antidote of MTX toxicity.